NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development
/
Date05 Dec 2016
– Company to pursue comparative bioavailability regulatory route instead of clinical efficacy development route –– NeuroDerm to add patients to its long-term safety trial ––... Read More →
Cesca Submits IDE Supplement for CLI Pivotal Trial
/
Date05 Dec 2016
RANCHO CORDOVA, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics,... Read More →
G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer
/
Date05 Dec 2016
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech,... Read More →
Dr. Samantha Stuart, DC Addresses Headache Causes and Treatment During the Holidays
/
Date04 Dec 2016
PORTLAND, Ore., Dec. 04, 2016 (GLOBE NEWSWIRE) — With the whirlwind of tasks to complete as individuals approach the holidays, it is no wonder that... Read More →
Clayton Chiropractic Provides Adjustments and Techniques for Local Athletic Wellness
/
Date04 Dec 2016
CLAYTON, N.C., Dec. 04, 2016 (GLOBE NEWSWIRE) — Athletes commonly use chiropractic treatments to reduce recovery time from current injuries, improve performance and avoid future... Read More →
uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
/
Date03 Dec 2016
— Second-dose Cohort Demonstrates Dose Response with All Patients Free of Prophylactic FIX Replacement Therapy and Only One Spontaneous Bleed Reported — Low-Dose Cohort Shows Sustained... Read More →
NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors
/
Date03 Dec 2016
Bagsværd, Denmark, 3 December 2016 – Novo Nordisk today announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of... Read More →
NovoSeven® standser 96,5% af blødningerne, når behandling iværksættes indenfor en time efter blødningens start hos mennesker med hæmofili A eller B med inhibitorer
/
Date03 Dec 2016
Bagsværd, den 3. december 2016 – Novo Nordisk præsenterer i dag resultater, der viser, at NovoSeven® (rFVIIa), et rekombinant aktiveret faktor VIIa-produkt, som er stabilt... Read More →
Insure.com Survey Publishes 2017's Best Health Insurance Companies for Baby Boomers
/
Date02 Dec 2016
FOSTER CITY, Calif., Dec. 2, 2016 (GLOBE NEWSWIRE) — Blue Cross Blue Shield of Michigan was ranked the top health insurance company for Baby Boomers... Read More →
Talyst to Debut AutoPharm(R) Analytics at ASHP Midyear Clinical Meeting
/
Date02 Dec 2016
KIRKLAND, Wash., Dec. 2, 2016 (GLOBE NEWSWIRE) — Talyst, a market leader in pharmacy automation and medication management solutions will be exhibiting at the 2016... Read More →